Related Experiment Video
Updated: Jun 11, 2026
An Alternative Culture Method to Maintain Genomic Hypomethylation of Mouse Embryonic Stem Cells Using MEK Inhibitor PD0325901 and Vitamin C
Published on: June 1, 2018
Arsenic disulfide promoted the demethylation of PTPL1 in diffuse large B cell lymphoma cells
Chen Chen1, Ling Wang1, Yan Liu2
1Department of Hematology, The Affiliated Taian City Central Hospital of Qingdao University, Taian, Shandong, China.
Background:
Promoter hypermethylation of the tumor suppressor gene is one of the well-studied causes of cancer development. The drugs that reverse the process by driving demethylation could be a candidate for anticancer therapy. This study was designed to investigate the effects of arsenic disulfide on PTPL1 methylation in diffuse large B cell lymphoma (DLBCL).
Methods:
We knocked down the expression of PTPL1 in two DLBCL cell lines (i.e., DB and SU-DHL-4 cells) using siRNA. Then the DLBCL proliferation was determined in the presence of PTPL1 knockdown. The methylation of PTPL1 in DLBCL cells was analyzed by methylation specific PCR (MSPCR). The effect of arsenic disulfide on the PTPL1 methylation was determined in DLBCL cell lines in the presence of different concentrations of arsenic disulfide (5 µM, 10 µM and 20 µM), respectively. To investigate the potential mechanism on the arsenic disulfide-mediated methylation, the mRNA expression of DNMT1, DNMT3B and MBD2 was determined.
Results:
PTPL1 functioned as a tumor suppressor gene in DLBCL cells, which was featured by the fact that PTPL1 knockdown promoted the proliferation of DLBCL cells. PTPL1 was found hypermethylated in DLBCL cells. Arsenic disulfide promoted the PTPL1 demethylation in a dose-dependent manner, which was related to the inhibition of DNMTs and the increase of MBD2.
Conclusion:
Experimental evidence shows that PTPL1 functions as a tumor suppressor gene in DLBCL progression. PTPL1 hyper-methylation could be reversed by arsenic disulfide in a dose-dependent manner.
Insights
Arsenic disulfide reverses tumor suppressor gene PTPL1 hypermethylation in diffuse large B cell lymphoma (DLBCL). This demethylation effect, observed in a dose-dependent manner, suggests potential for novel anticancer therapies targeting DLBCL.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Promoter hypermethylation of tumor suppressor genes is a key driver of cancer development.
- Demethylating agents are potential anticancer therapeutics.
- This study investigates arsenic disulfide's effect on PTPL1 methylation in diffuse large B cell lymphoma (DLBCL).
Purpose of the Study:
- To determine the role of PTPL1 as a tumor suppressor gene in DLBCL.
- To analyze the impact of arsenic disulfide on PTPL1 methylation in DLBCL cells.
- To elucidate the molecular mechanisms underlying arsenic disulfide's effect on PTPL1 methylation.
Main Methods:
- PTPL1 knockdown in DLBCL cell lines (DB and SU-DHL-4) using siRNA.
- Assessment of DLBCL proliferation following PTPL1 knockdown.
- Methylation-specific PCR (MSPCR) to analyze PTPL1 methylation.
- Treatment of DLBCL cells with varying concentrations of arsenic disulfide (5 µM, 10 µM, 20 µM).
- Quantification of DNMT1, DNMT3B, and MBD2 mRNA expression.
Main Results:
- PTPL1 acts as a tumor suppressor in DLBCL, as its knockdown promotes cell proliferation.
- PTPL1 was found to be hypermethylated in DLBCL cells.
- Arsenic disulfide induced PTPL1 demethylation in a dose-dependent manner.
- The demethylation effect correlated with DNMT inhibition and MBD2 upregulation.
Conclusions:
- PTPL1 functions as a tumor suppressor gene in DLBCL progression.
- Arsenic disulfide effectively reverses PTPL1 hypermethylation in a dose-dependent manner, indicating therapeutic potential.
